GlassScriptPhysician profile
Sami Abu Farha
NPI 1104895697
$11,401.33
in general payments reported to CMS, 2019-2025
46 companies · $2,618 in 2025
The $2,618 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $1,336 · 2021: $1,769 · 2022: $1,661 · 2023: $1,379 · 2024: $1,521 · 2025: $2,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,456 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,456.23 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,540.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,052.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $957.88 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $945.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Ironwood Pharmaceuticals, INC | $819.14 | 2019-2024 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $730.57 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $678.41 | 2020-2025 | Vraylar, Linzess, Creon |
| Amgen INC. | $676.64 | 2019-2025 | Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $424.83 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $405.65 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $289.45 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.48 | 2019-2025 | Xifaxan |
| Pfizer INC. | $267.35 | 2019-2025 | |
| Astellas Pharma US INC | $238.86 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $202.71 | 2021-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Abu Farha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.